1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
Treatment characteristics
No. and Type of Aneurysms (%)PGLA-Coated Coils (All)100% PGLA-Coated CoilsBare Platinum Coils
Stent-assisted18/82 (22%)8/42 (19%)1/80 (1%)
Balloon remodeling7/82 (9%)1/42 (2%)18/80 (23%)
Total treated with adjunctive device25/82 (30%)9/42 (21%)19/80 (24%)
Intentional subtotal embolization to preserve parent vessel2/82 (2%)1/42 (2%)4/80 (5%)
  • Note:—PGLA indicates polyglycolic/polylactic acid.